You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HBsAg clearance

Showing 1 - 25 of 2,005
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Hepatitis B Trial in Hannover (Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®))

Recruiting
  • Chronic Hepatitis B
  • Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)
  • Hannover, Lower Saxony, Germany
    Hannover Medical School, Department for Gastroenterology, Hepato
May 31, 2022

Chronic Hepatitis B Trial in Hong Kong (Stop current treatment (anti-HBV neucleos(t)ides), Keep current treatment (anti-HBV

Recruiting
  • Chronic Hepatitis B
  • Stop current treatment (anti-HBV neucleos(t)ides)
  • Keep current treatment (anti-HBV neucleos(t)ides)
  • Hong Kong, Hong Kong SAR, Hong Kong
    Humanity & Health Research Centre
Mar 16, 2022

Chronic Hepatitis B Trial in Zhengzhou (PegIFN a- 2b)

Completed
  • Chronic Hepatitis B
  • PegIFN α- 2b
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Jul 11, 2022

Chronic Hepatitis B, High-Risk Cancer Trial in China (Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue, Nucleos(t)ide

Active, not recruiting
  • Chronic Hepatitis B
  • High-Risk Cancer
  • Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue
  • Nucleos(t)ide analogue
  • Chengdu, China
  • +8 more
Jan 4, 2023

Chronic Hepatitis B Trial in Zhengzhou (continuous treatment, pulse therapy)

Recruiting
  • Chronic Hepatitis B
  • continuous treatment
  • pulse therapy
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Jul 13, 2022

Hepatitis B, Chronic Trial in Worldwide (administration of SLGN in arm C, Discontinuation of NUC treatment in arms B and C)

Recruiting
  • Hepatitis B, Chronic
  • administration of SLGN in arm C
  • Discontinuation of NUC treatment in arms B and C
  • Lyon, France
  • +7 more
Mar 11, 2022

Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)

Recruiting
  • Lymphoma, B-Cell
  • Rituximab Biosimilar
  • Pegylated Interferon α-2b
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022

Chronic Hepatitis B Trial in Beijing (PEG-IFN)

Recruiting
  • Chronic Hepatitis B
  • Beijing, Beijing, China
    Department of Hepatology Division 2, Beijing Ditan Hospital
May 9, 2022

Chronic Hepatitis B Trial in Beijing (PEG-IFN)

Recruiting
  • Chronic Hepatitis B
  • Beijing, Beijing, China
    Department of Hepatology Division 2, Beijing Ditan Hospital
May 9, 2022

Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia Trial in Fuzhou (Peginterferon alpha-2b, Nucleotide Analog,

Recruiting
  • Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia
  • Peginterferon alpha-2b
  • +2 more
  • Fuzhou, Fujian, China
    Fuzhou General Hospital, Xiamen Univ
Jan 21, 2022

Hepatitis B Virus Infection Trial in Changsha (Standard antiviral therapy)

Recruiting
  • Hepatitis B Virus Infection
  • Standard antiviral therapy
  • Changsha, Hunan, China
    Department of Infectious Disease, Xiangya Hospital, Central Sout
May 22, 2022

Hepatitis B, Chronic Trial in Worldwide (HepTcell, Placebo)

Recruiting
  • Hepatitis B, Chronic
  • HepTcell
  • Placebo
  • Garden Grove, California
  • +20 more
Dec 1, 2021

HBeAg-negative CHB Patients With Indeterminate Phase

Recruiting
  • Chronic Hepatitis b
  • Observation
  • Antiviral treatment
  • Changzhou, Jiangsu, China
  • +4 more
Dec 21, 2022

Chronic Hepatitis B Trial run by the NIDDK (hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN))

Withdrawn
  • Chronic Hepatitis B
  • hepatitis B immune globulin (HBIg)
  • Pegylated interferon alfa (pegIFN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 4, 2022

Hepatitis B, Chronic Trial in Toronto (Tenofovir disoproxil fumarate)

Active, not recruiting
  • Hepatitis B, Chronic
  • Tenofovir disoproxil fumarate
  • Toronto, Ontario, Canada
    University Health Network - Toronto General Hospital
Nov 1, 2022

Hepatitis B Trial in Worldwide (GSK3228836, Placebo, Nucleos(t)ide therapy)

Completed
  • Hepatitis B
  • Los Angeles, California
  • +120 more
Jul 1, 2022

Chronic Hepatitis b Trial (RBD1016, RBD1016+PegIFN-a)

Not yet recruiting
  • Chronic Hepatitis b
  • (no location specified)
Jul 25, 2023

Hepatitis b Virus Trial in New York (HepB mAb19, Sterile Saline)

Not yet recruiting
  • Hepatitis b Virus
  • HepB mAb19
  • Sterile Saline
  • New York, New York
  • +1 more
May 12, 2023

Tenofovir Disoproxil Fumarate and Entcavir in Treatment of

Recruiting
  • Chronic Hepatitis b Patients
  • Tenofovir Disoproxil Fumarate and Entcavir
  • Sohag, Egypt
    Sohag University hospitals
May 22, 2023

Chronic Hepatitis b Trial in Guangzhou (Vitamin D)

Completed
  • Chronic Hepatitis b
  • Vitamin D
  • Guangzhou, Guangdong, China
    Department of Infectious Diseases, The Third Affliated Hospital
Mar 2, 2023

Chronic Hepatitis b Trial in Chongqing, Xi'an (Placebo, TQA3605 tablets, Entecavir dispersible tablets)

Recruiting
  • Chronic Hepatitis b
  • Placebo
  • +4 more
  • Chongqing, Chongqing, China
  • +2 more
Nov 27, 2023

Hepatitis B, Chronic Trial in Beijing, Changchun (VIR-2218, Placebo)

Completed
  • Hepatitis B, Chronic
  • Beijing, Beijing, China
  • +1 more
Jul 26, 2022

Hepatitis B, Chronic Trial in Worldwide (DCR-HBVS, Placebo for DCR-HBVS)

Completed
  • Hepatitis B, Chronic
  • Clayton, Victoria, Australia
  • +8 more
Sep 28, 2022

TriQuik Invitro Diagnostic Device

Not yet recruiting
  • To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device
  • TriQuik IVD
  • (no location specified)
Jan 11, 2023

HBsAg Declined Patients Follow-up Study

Not yet recruiting
  • Hepatitis B
  • Hepatitis B, Chronic
    • (no location specified)
    Jul 28, 2023